The performance of a norovirus antigen detection assay was assessed using monoclonal antibody NV23 and single-chain antibody HJT-R3-A9 to identify both virus-like particles and virus-containing fecal samples. The detection of 25 different norovirus genotypes as recombinant virus-like particles or in clinical samples was dependent on virus or antigen concentration. N oroviruses are a major cause of acute nonbacterial gastroenteritis in humans (1). Noroviruses are genetically highly diverse and have been classified into seven genogroups, three of which contain human strains. These genogroups are further subdivided into at least 41 genotypes based upon the amino acid sequence of the major capsid protein, VP1 (2). The diversity of genotypes has been a barrier to the development of sensitive, broadly reactive antigen detection assays. The development of monoclonal (3) and human single-chain (4) antibodies (MAbs and single-chain variable fragment [scFv], respectively) that recognize many different norovirus strains led us to assess a combination of these reagents for identification of noroviruses in fecal samples.
N
oroviruses are a major cause of acute nonbacterial gastroenteritis in humans (1) . Noroviruses are genetically highly diverse and have been classified into seven genogroups, three of which contain human strains. These genogroups are further subdivided into at least 41 genotypes based upon the amino acid sequence of the major capsid protein, VP1 (2) . The diversity of genotypes has been a barrier to the development of sensitive, broadly reactive antigen detection assays. The development of monoclonal (3) and human single-chain (4) antibodies (MAbs and single-chain variable fragment [scFv] , respectively) that recognize many different norovirus strains led us to assess a combination of these reagents for identification of noroviruses in fecal samples.
Recombinant norovirus virus-like particles (VLPs) served as the antigen in initial studies and were generated using a baculovirus expression system, as previously described (3). Recombinant clones were generated either by amplification of viral genomes from clinical samples or by in vitro synthesis of viral genes from GenBank sequences (Epoch Life Science, Ltd., Missouri City, TX). Expressed VLPs were purified using cesium chloride gradients. Adequacy of the VLP structure was confirmed by electron microscopy, and VLP protein concentrations were determined with a Pierce bicinchoninic acid (BCA) protein assay kit (Thermo Scientific, Rockford, IL) using bovine serum albumin as a reference standard. Fecal samples collected in previous clinical studies (5, 6) were characterized for the presence of noroviruses by conventional reverse transcription (RT)-PCR and were used in the current study under protocols approved by the Baylor College of Medicine Institutional Review Board. Each sample was from a unique individual; samples were selected to represent an array of different genotypes from available specimens. Genotype was assigned by sequencing of the 5= end of the VP1 gene, and virus concentration was determined semiquantitatively by real-time RT-quantitative PCR (qPCR) with a StepOnePlus real-time PCR system (Applied Biosystems, Foster City, CA) using Cog1F/Cog1R/Ring1C and Cog2F/Cog2R/Ring2 primers and probes for genogroup I (GI) and GII strains, respectively (7, 8) . Viral RNA was isolated with a QIAamp viral RNA minikit (Qiagen, Mainz, Germany). A sample with a cycle threshold (C T ) value under 40 was considered positive. Negative samples were assigned a C T value of 40 for graphic display.
We previously generated and characterized a panel of MAbs and scFvs that recognize norovirus antigens (3) (4) (5) . For this study, we selected MAb NV23, which recognizes an epitope on the VP1 protruding domain of GI, GII, and GIV noroviruses, and scFv HJT-R3-A9 (A9), which recognizes an epitope on the VP1 shell domain, for further study. A sandwich ELISA utilized NV23 (3 g/ml) for antigen capture and A9 protein (5 g/ml) for detection. Briefly, 96-well plates were coated with MAb NV23 in 100 l phosphate-buffered saline (PBS) overnight at 4°C. Each well was blocked with 10% low-fat milk in PBS for 2 h at room temperature. After washing, 100 l of VLPs (0.01 to 3 g/ml) or a 2.5% stool suspension (in distilled water) was added for a 1-h incubation at 37°C. After washing, A9 was added and incubated for 2 h at room temperature, followed by the addition of a horseradish peroxidase-conjugated secondary antibody (1:5,000 of polyclonal anti-Myc antibody) for another 45 min. Tetramethylbenzidine was added to develop the signal, the reaction was stopped with 1 M H 3 PO 4 , and the plates were read at 450 nm with a SpectraMax 190 microplate reader (3, 4) . A positive result was considered to be an optical density (OD) value that was 0.1 greater than the mean negative-control reagent OD plus 3 standard deviations (SD).
The initial studies utilized recombinant norovirus virus-like particles (VLPs) as the antigen. As shown by the results in Table 1 , VLPs from 28 strains representing 23 norovirus genotypes were detected in the assay. The limits of detection ranged from 1 to 10 ng/well for the 8 GI genotypes evaluated. A similar limit of detection was observed for 13 of the 14 GII genotypes assessed, with only GII.7 strains having a higher limit of detection of 50 ng/well. The highest limit of detection was for the GIV.1 strain at 100 ng/well.
We next assessed 53 fecal samples containing noroviruses representing 17 different genotypes, along with 20 norovirusnegative stool samples. Forty-four of the norovirus-containing stool samples were positive in the antigen detection assay, while none of the norovirus-negative samples were positive. Nine fecal samples containing noroviruses from 6 different genotypes were negative in the antigen assay. We next assessed the influence of viral load, as determined by RT-qPCR, on antigen detection results. All samples with a C T value of Ͻ31 were positive in the antigen detection assay, while all norovirus-containing samples that were negative in the antigen detection assay had a C T value of Ͼ31 ( 2 ϭ 23.4, P Ͻ 0.001). Six virus-containing samples were positive by antigen detection and were negative in the RT-qPCR assay (assigned a value of 40). We suspected that the negative RT-qPCR results for the GI strains were due to sensitivity problems of the assay for certain GI genotypes. We used a different RT-qPCR assay (9) to determine C T values for the six GI strains that were negative in the original RT-qPCR assay, and all had viral RNA identified at C T values ranging from 21 to 37 (Fig. 1) , indicating that the antigen assay results were true positives and that the original RTqPCR assay used for detection of GI noroviruses did not identify several strains used in this study.
The low sensitivity of norovirus antigen detection assays has been a limitation in applying such assays to clinical samples (2).
In the current study, we found a correlation between the antigen detection assay result and the level of virus present in the clinical sample, as determined by RT-qPCR. The two norovirus ligands used, MAb NV23 and scFv HJT-R3-A9, were able to identify all norovirus genotypes present in stool samples at a C T value of Ͻ31 and as little at 10 ng of VLPs for most norovirus genotypes. A threshold C T value for distinguishing between symptomatic and subclinical disease caused by rotavirus infection has been reported, with antigen detection assays being positive at C T values below the threshold (10). A similar threshold for RT-qPCR has also been suggested for norovirus infection (11) , and our data suggest that antigen detection assays could also perform in a fashion similar to what was observed with rotavirus antigen assays. Limitations of the work include that we did not test all known human norovirus genotypes and that the C T values we identified in our laboratory as a cutoff may be different in other laboratories, based upon the RTqPCR assay used. We suggest that future studies of norovirus antigen detection assays should consider viral load in assessing assay performance. 
